Product Categories
| Country: | China |
|---|---|
| Tel: | 027-027-19050701 |
| Mobile: | 13545374703 |
| E-mail: | |
| QQ: | |
| Skype: | Chat Now! |
| Product Name | MF | CAS | Details |
|---|
| β-NETA intermediate | C15H17NO | 2752-87-6 | Details |
| RO5263397 | C10H11FN2O | 1357266-05-7 | Details |
| Milrinone impurity Z06 | C14H14N2O3 | 80442-07-5 | Details |
| Milrinone impurity Z12 | C8H9NO | 6302-02-9 | Details |
| Milrinone impurity Z11 | C8H9NO | 6302-03-0 | Details |
| Milrinone impurity Z09 | C12H9N3O2 | 156033-07-7 | Details |
| Tolterodine impurity Z10 | C29H37NO | 848768-06-9 | Details |
| Tolterodine impurity Z14 | C26H37NO3 | 1380491-70-2 | Details |
| Tolterodine impurity Z12 | C16H18O2 | 851789-43-0 | Details |
| Tolterodine impurity Z11 | C16H16O2 | 209747-04-6 | Details |
| Pantothenicacid calciumsalt impurity D | C10H19NO5 | 50692-78-9 | Details |
| Pantothenicacid calciumsalt impurity E | C12H22N2O6 | 897045-90-8 | Details |
| Tolterodine impurity Z25 | C17H18O3 | 109089-77-2 | Details |
| Tolterodine impurity Z17; 2-(3-amino-1-phenylpropyl)-4-methylphenol hydrochloride | Details |
| Pantothenicacid calciumsalt impurity G | C6H12N2O3 | 2140-53-6 | Details |
| Pantothenicacid calciumsalt impurity H; 3-(5-(1-hydroxy-2-methylpropan-2-yl)-4-oxooxazolidin-3-yl)propanoic acid | Details |
| Pantothenicacid calciumsalt impurity C | C6H10O3 | 599-04-2 | Details |
| Pantothenicacid calciumsalt impurity Z04; ethyl (R)-3-(2,4-dihydroxy-3,3-dimethylbutanamido)propanoate | Details |
| Pantothenicacid calciumsalt impurity B | Details |
| Tolterodine impurity Z08 | C35H41NO2 | 854306-72-2 | Details |
| Tolterodine impurity D; N-isopropyl-3-(2-methoxy-5-methylphenyl)-3-phenylpropan-1-amine hydrochloride | C20H27NO | 1391053-65-8 | Details |
| Tolterodine impurity Z09 | C16H14O2 | 40546-94-9 | Details |
| Tolterodine impurity A | C17H20O2 | 124937-73-1 | Details |
| Tolterodine impurity Z07 | C23H33NO4 | 380636-49-7 | Details |
| Tolterodine impurity G | C22H32NO2+ | 1554029-91-2 | Details |
| Milrinone impurity Z07 | C12H9N3O | 106637-42-7 | Details |
| Milrinone impurity Z05 | C12H10N2O3 | 80047-38-7 | Details |
| Pantothenicacid calciumsalt impurity Z05 | C6H11NO4 | 505-47-5 | Details |
| Milrinone impurity Z02 | C7H6N4O2 | 717818-05-8 | Details |
| formoterol impurity E | C20H26N2O4 | 1616967-26-0 | Details |
| formoterol impurity A | C18H24N2O3 | 150513-24-9 | Details |
| formoterol impurity H | C26H30N2O4 | 1337876-26-2 | Details |
| formoterol impurity F | C37H46N4O6 | 1795129-59-7 | Details |
| formoterol impurity C | C20H26N2O4 | 1795135-61-3 | Details |
| Norfloxacin impurity D | C15H18FN3O | 75001-82-0 | Details |
| Norfloxacin impurity Z13; 9-chloro-6-ethyl-8-fluoro-4-oxo-4,6-dihydro-2H-1l3,2l4-[1,3,2]dioxaborinino[5,6-c]quinoline-2,2-diyl diacetate | Details |
| Norfloxacin impurity G | C17H18FN3O4 | 70459-04-0 | Details |
| Norfloxacin impurity H | C19H22FN3O5 | 105440-01-5 | Details |
| formoterol impurity I | C19H24N2O4 | 67346-50-3 | Details |
| Norfloxacin impurity Z04 | C12H11FN2O3 | 75001-63-7 | Details |
| formoterol impurity D | C20H26N2O4 | 1795133-96-8 | Details |
| formoterol impurity G | 3706-26-1 | Details |
| formoterol impurity B | C18H22N2O4 | 1224588-66-2 | Details |
| Norfloxacin impurity J; 6,7-bis(4-(ethoxycarbonyl)piperazin-1-yl)-1-ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | Details |
| Norfloxacin impurity B | C14H16FN3O3 | 75001-77-3 | Details |
| Rivaroxaban impurity05 | Details |
| Norfloxacin impurity A | C12H9ClFNO3 | 68077-26-9 | Details |
| Rivaroxaban impurityK | C36H36N6O10 | 1365267-36-2 | Details |
| Rivaroxaban impurity02 | C28H34N6O8 | 1879933-39-7 | Details |
| Rivaroxaban impurityJ | C38H36Cl2N6O10S2 | 1632463-24-1 | Details |
| Rivaroxaban impurity03 | C22H21N3O7 | 1365267-37-3 | Details |
| Rivaroxaban impurity04 | C14H17N3O4 | 1411775-06-8 | Details |
| Rivaroxaban impurity01; | C24H19Cl2N3O6S2 | Details |
| Rivaroxaban impurityG | C22H19N3O6 | 446292-08-6 | Details |
| Tolterodine impurity C | C22H31NO | 1161940-88-0 | Details |
| Milrinone impurity Z10 | C14H15N3O2 | 2153433-47-5 | Details |
| β-NETA | C16H20NO.I | 31059-54-8 | Details |
| Rivaroxaban impurityA | C19H18ClN3O5S | 865479-71-6 | Details |
| Rivaroxaban impurityH | C19H17Cl2N3O5S | 1770812-37-7 | Details |
| Rivaroxaban impurityD | C29H32N6O9 | 1365267-35-1 | Details |
| Rivaroxaban impurityB | C16H19N3O5 | 1429334-00-8 | Details |
| Rivaroxaban impurityF | C5H3ClO2S | 24065-33-6 | Details |
| Rivaroxaban impurityE | C19H19N3O5S | 1415566-28-7 | Details |
| Sitagliptin impurity A | C16H15F6N5O | 823817-55-6 | Details |
| Sitagliptin impurity FP-C | C16H12F6N4O | 1803026-58-5 | Details |
| Sitagliptin impurity C | C16H16F5N5O | 945261-48-3 | Details |
| Sitagliptin impurity B | C16H16F5N5O | 486460-31-5 | Details |
| Sitagliptin impurity FP-A | C20H19F6N5O5 | 2088771-60-0 | Details |
| Sitagliptin impurity FP-D | C16H12F6N4O | 1253056-18-6 | Details |
| Topiroxostat impurity 01 | C13H7N5O | 2044704-74-5 | Details |
| Topiroxostat impurity 05 | C12H10N6 | 31599-25-4 | Details |
| Topiroxostat impurity 06 | C13H9N5O2 | 2044702-36-3 | Details |
| Sitagliptin impurity FP-E | C10H10F3NO2 | 936630-57-8 | Details |
| Topiroxostat impurity 03 | C20H12N10 | 2044706-78-5 | Details |
| Topiroxostat impurity 09 | C13H10N6O | 1841081-71-7 | Details |
| Topiroxostat impurity 07 | C13H10N6O | 1992028-94-0 | Details |
| Topiroxostat impurity 04; 4,4'-(5,5'-(pyridine-2,4-diyl)bis(4H-1,2,4-triazole-5,3-diyl))dipyridine | Details |
| Topiroxostat impurity 02 | C12H10N6 | 38634-05-8 | Details |
| Tolterodine impurity E | C19H25NO | 480432-14-2 | Details |
| Topiroxostat impurity 25; 4-(5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)picolinohydrazide | Details |
| Topiroxostat impurity 23 | C7H9N5O2 | 21379-40-8 | Details |
| Topiroxostat impurity 24; methyl 4-(5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)picolinate | Details |
| Topiroxostat impurity 28; (Z)-isonicotinohydrazonamide | Details |
| Topiroxostat impurity 10 | C13H8N6O | 577778-82-6 | Details |
| Topiroxostat impurity 20 | C7H4N2O2 | 161233-97-2 | Details |
| Topiroxostat impurity 22 | C7H6N4O | 2050015-91-1 | Details |
| Topiroxostat impurity 18 | C7H6N4O | 135048-32-7 | Details |
| Topiroxostat impurity 13 | C13H12N8 | 2044706-50-3 | Details |
| Topiroxostat impurity 19 | C13H8N6 | 2044706-68-3 | Details |
| Topiroxostat impurity 16 | C12H9N5 | 4329-78-6 | Details |
| Topiroxostat impurity 12; 2-cyano-4-(3-(1-oxidopyridin-4-yl)-1H-1,2,4-triazol-5-yl)pyridine 1-oxide | Details |
| Topiroxostat impurity 17 | C12H9N5O | 36770-53-3 | Details |
| Topiroxostat impurity 14 | C6H7N3O2 | 6975-73-1 | Details |
| Topiroxostat impurity 21; 2-cyanoisonicotinamide | C7H5N3O | 98273-47-3 | Details |
| Topiroxostat impurity 11 | C7H10N6O | 2044708-04-3 | Details |
| Krass intermediate 01 | 2936672-10-3 | Details |
| Sitagliptin impurity FP-B | C16H13F6N5O2 | 2805078-75-3 | Details |
| 2936672-09-0 | Details |
| RO5166017 | C12H17N3O | 1048346-74-2 | Details |
| Norfloxacin impurity C | C20H27N5O3 | 177554-64-2 | Details |
| Product Total： Product Page： | ||||
| 1 2 3 4 | ||||